Drugs Containing Excipient (Inactive Ingredient) ALUMINUM SULFATE

« Back to Dashboard

Generic drugs containing ALUMINUM SULFATE excipient

Company	Ingredient	NDC	Excipient
Cosette Pharmaceuticals Inc	desonide	0713-0661	ALUMINUM SULFATE
Alembic Pharmaceuticals Limited	desonide	46708-632	ALUMINUM SULFATE
Unit Dose Services	desonide	50436-3300	ALUMINUM SULFATE
Alembic Pharmaceuticals Inc	desonide	62332-632	ALUMINUM SULFATE
Bryant Ranch Prepack	desonide	63629-2506	ALUMINUM SULFATE

Aluminum Sulfate Pharmaceutical Excipient Market Dynamics and Financial Trajectory

Last updated: October 22, 2026

Aluminum sulfate, CAS No. 10043-01-3, is a low-volume pharmaceutical excipient and process material compared with its much larger water-treatment, paper, and industrial markets. Its pharmaceutical economics are driven by qualification, purity, supply continuity, and regulatory documentation rather than patent exclusivity. Public companies generally do not report aluminum sulfate pharmaceutical sales separately, so a precise standalone market size or revenue forecast is not available from audited disclosures.

Pharmaceutical demand is likely to remain stable but niche. The main commercial risks are substitution by aluminum hydroxide, aluminum phosphate, synthetic astringents, and other aluminum salts; raw-material and energy-price volatility; and the limited number of suppliers that can support pharmaceutical-grade documentation.

What is aluminum sulfate used for in pharmaceutical products?

Aluminum sulfate is an inorganic aluminum salt with the formula Al2(SO4)3. Commercial material is sold in anhydrous or hydrated forms, including octadecahydrate grades. Its pharmaceutical use depends on grade, concentration, route of administration, and the regulatory status of the finished product.

Attribute	Commercial description
Chemical name	Aluminum sulfate
CAS number	10043-01-3
Molecular formula	Al2(SO4)3
Common forms	Anhydrous and hydrated salts
Pharmaceutical role	Excipient, astringent, processing aid, or formulation ingredient depending on use
Principal nonpharma markets	Drinking-water treatment, wastewater treatment, paper, textiles, and industrial processing
Typical commercial constraint	Trace-metal control, insoluble matter, microbiological quality, and lot consistency

In pharmaceutical and personal-care formulations, aluminum sulfate may be used for astringent or topical functions. Its use is materially smaller than the use of aluminum hydroxide and aluminum phosphate in vaccine formulations and antacid products. Aluminum sulfate should not be treated as interchangeable with those compounds without formulation, toxicology, and regulatory review.

The FDA Inactive Ingredient Database is the relevant starting point for evaluating precedent in approved drug products. An IID listing indicates prior use in an approved product, but it does not establish universal safety for every route, concentration, dosage form, or patient population.[1]

How large is the pharmaceutical aluminum sulfate market?

No standardized public market category isolates pharmaceutical-grade aluminum sulfate from the broader aluminum sulfate market. Industry market reports usually combine water-treatment, paper, industrial, and chemical-grade sales. Those reports therefore overstate the addressable pharmaceutical opportunity.

The pharmaceutical segment is best characterized as a specialty subsegment with the following commercial profile:

Market factor	Effect on pharmaceutical aluminum sulfate
Demand volume	Low relative to municipal and industrial water-treatment demand
Customer concentration	High; purchases are concentrated among formulation developers, contract manufacturers, and distributors
Pricing	Higher than commodity grade, but qualification and documentation support the premium
Switching cost	Moderate to high after approval because supplier changes may require comparability work
Patent protection	Generally limited; value is in quality systems and customer qualification
Growth profile	Low-to-moderate volume growth, with pricing influenced by feedstock and energy costs
Revenue visibility	Limited because suppliers rarely disclose pharmaceutical-grade sales separately

The pharmaceutical market can produce attractive margins for a qualified supplier even when absolute volume is small. The commercial value comes from recurring supply, validated specifications, regulatory files, and reliable delivery rather than scale alone.

What drives the financial trajectory for aluminum sulfate suppliers?

The financial trajectory is primarily a function of commodity input costs and demand in nonpharmaceutical end markets.

Raw-material and energy exposure

Aluminum sulfate production commonly depends on sulfuric acid and aluminum-bearing feedstocks such as alumina, aluminum hydroxide, bauxite-derived intermediates, or industrial aluminum trihydrate. Electricity, sulfur, transportation, and packaging costs affect delivered economics.

The U.S. Geological Survey tracks aluminum-related mineral and chemical production but does not publish a separate pharmaceutical aluminum sulfate revenue series.[2] Supplier profitability therefore tends to follow:

1. sulfuric acid and sulfur economics;
2. alumina and aluminum hydroxide costs;
3. natural gas and electricity prices;
4. freight and hazardous-material transport costs;
5. water-treatment demand and municipal purchasing cycles.

Pharmaceutical customers can absorb some cost inflation because switching suppliers is burdensome. That pricing protection is weaker where the excipient is used in a noncritical topical product with readily available substitutes.

End-market diversification

Water treatment is the dominant demand center for aluminum sulfate. Municipal drinking-water and wastewater applications create substantially larger volumes than pharmaceutical formulations. Suppliers with exposure to both markets can offset weak pharmaceutical demand with industrial sales.

Chemtrade Logistics, Kemira, and regional specialty chemical producers report water-treatment and inorganic chemical activities, but their public filings do not isolate pharmaceutical aluminum sulfate revenue.[3][4] The absence of separate disclosure means investors should not attribute the performance of an entire aluminum sulfate business to pharmaceutical demand.

Qualification premiums

Pharmaceutical-grade material can command a premium over technical or water-treatment grade because customers may require:

• controlled impurity profiles;
• documented manufacturing changes;
• traceability;
• validated cleaning and packaging;
• certificates of analysis;
• change-control notifications;
• audit access;
• compendial or customer-specific testing.

The premium is strongest when the material is used in an approved product and the supplier is listed in the customer’s regulatory documentation.

What regulatory status applies to aluminum sulfate as a pharmaceutical excipient?

Aluminum sulfate is not approved as a drug in the same manner as an active pharmaceutical ingredient. Its regulatory position depends on its role in a specific finished product.

FDA review generally focuses on the finished dosage form, the intended route, exposure level, product quality, and the justification for each inactive ingredient. The IID provides historical precedent but does not eliminate the need for product-specific assessment.[1]

FDA and United States status

For a new drug, an applicant must identify and justify inactive ingredients in the relevant regulatory submission. For an ANDA, the proposed product generally must match the reference product in active ingredient, dosage form, strength, route, and other requirements under the abbreviated pathway.[5]

Aluminum sulfate is not an independent Orange Book-listed drug product merely because it is used as an excipient. The Orange Book identifies approved drug products and associated patents and exclusivity, not commodity excipient suppliers.[6]

European and international status

European pharmaceutical use is assessed under the applicable excipient and finished-product framework, including quality documentation, pharmacopoeial expectations where applicable, and risk assessment for elemental impurities. ICH Q3D is relevant when aluminum is evaluated as an elemental impurity in drug products, although the regulatory analysis depends on the product, route, and exposure.[7]

A supplier seeking international sales may need region-specific documentation covering GMP controls, manufacturing sites, elemental impurities, residual solvents where relevant, microbiological quality, and change control.

What quality specifications matter for pharmaceutical-grade aluminum sulfate?

The commercial distinction between pharmaceutical and industrial material is based on the control system and specification package, not simply the chemical name.

Important quality attributes include:

Quality attribute	Commercial relevance
Assay and hydration state	Controls composition and batch comparability
Insoluble matter	Affects clarity, filtration, and finished-product appearance
Iron and heavy metals	Can affect color, stability, and toxicological assessment
Lead, arsenic, cadmium, and mercury	Relevant to elemental-impurity risk management
Residual processing impurities	Must be assessed against product-specific limits
Microbiological quality	Important for topical, oral, and aqueous products
Particle size	Relevant to dispersion and dissolution
pH and solution clarity	Important for formulation compatibility
Packaging integrity	Protects against moisture uptake and contamination

Aluminum sulfate is hygroscopic in some commercial forms and may change physical characteristics during storage. Packaging, temperature, humidity, and transport controls can therefore affect the usable shelf life.

What patents protect aluminum sulfate pharmaceutical formulations?

The underlying aluminum sulfate molecule is old and is not a realistic target for new composition-of-matter exclusivity. Any relevant patent protection would more likely cover:

• a specific topical formulation;
• a particular concentration or pH range;
• a combination with another active or excipient;
• a controlled-release or specialty delivery system;
• a manufacturing or purification process;
• a defined therapeutic use.

Patent value is usually attached to the finished drug product, not to aluminum sulfate as a commodity ingredient. A formulation patent may list aluminum sulfate among many optional excipients without creating meaningful commercial protection for the salt itself.

Patent expiration and freedom-to-operate

A credible patent-expiration analysis requires a defined formulation, jurisdiction, assignee, and product. There is no single expiration date for "aluminum sulfate pharmaceutical excipient" because different patents could cover different formulations or methods.

For U.S. products, relevant patents may appear in the Orange Book if they claim an approved drug product or method of use and meet listing requirements. Supplier manufacturing patents and formulation patents may instead appear only in ordinary patent databases and may not be listed in the Orange Book.[6]

Are Paragraph IV challenges relevant to aluminum sulfate?

Paragraph IV litigation applies to an ANDA applicant’s certification that a listed patent is invalid, unenforceable, or will not be infringed. It is relevant to a finished drug product containing aluminum sulfate only if that product has an applicable Orange Book-listed patent.[5]

It is not a normal pathway for challenging the excipient itself. A generic manufacturer can often source aluminum sulfate from an alternative supplier without filing a Paragraph IV certification, provided the finished product satisfies applicable quality and equivalence requirements.

The commercial risk is therefore more likely to arise from supplier qualification, formulation equivalence, or manufacturing documentation than from direct excipient patent litigation.

What manufacturing and intellectual-property barriers affect supply?

The principal barriers are operational rather than patent-based.

Manufacturing barriers

A supplier must control:

• feedstock purity;
• contamination from iron and other metals;
• hydration state;
• batch-to-batch assay;
• filtration and crystallization;
• packaging and moisture control;
• site changes and process changes;
• supply continuity during commodity-market disruptions.

A water-treatment-grade producer may have suitable chemistry but still fail to meet a pharmaceutical customer’s documentation, audit, or change-control requirements. This creates a qualification barrier that can protect incumbent suppliers.

Intellectual-property barriers

IP may protect proprietary purification, crystallization, particle engineering, or formulation processes. Such rights are typically narrower than a basic chemical patent and may be difficult to detect from product-level market data.

The strongest defensibility comes from the combination of:

• a validated manufacturing process;
• regulatory history;
• customer-specific specifications;
• multi-year supply performance;
• approved supplier status;
• technical support.

Which companies compete in aluminum sulfate supply?

Competition is fragmented geographically and is dominated by chemical producers with broader portfolios. Relevant supplier groups include:

Supplier group	Competitive advantage
Large water-treatment chemical producers	Scale, logistics, municipal relationships
Specialty inorganic chemical producers	Higher-purity grades and technical support
Regional manufacturers	Lower freight costs and local availability
Chemical distributors	Inventory access and multi-source procurement
Integrated aluminum or sulfur chemical companies	Feedstock and process integration

Kemira and Chemtrade are examples of publicly visible companies with significant water-treatment chemical exposure, while regional producers and private companies serve local markets. Their reported financial results should be interpreted as portfolio-level indicators, not direct measures of pharmaceutical aluminum sulfate performance.[3][4]

How does aluminum sulfate compare with competing aluminum excipients?

Material	Common pharmaceutical relevance	Relative commercial position
Aluminum sulfate	Astringent, topical, specialty formulation uses	Niche
Aluminum hydroxide	Antacid and vaccine-adjuvant applications	Broad pharmaceutical use
Aluminum phosphate	Vaccine adjuvant and formulation applications	Specialized but established
Aluminum oxide	Antacid, adsorbent, and abrasive uses	Product-dependent
Aluminum chloride	Antiperspirant and topical treatment products	Stronger branded-product exposure
Calcium or zinc salts	Astringent or therapeutic substitutes	Route- and formulation-dependent

Aluminum hydroxide and aluminum phosphate generally have stronger pharmaceutical relevance because of established use in vaccines and antacid products. Aluminum sulfate competes where its sulfate chemistry, astringency, solubility, or formulation behavior provides a specific advantage.

What is the revenue exposure and financial outlook?

The financial outlook is stable but modest at the pharmaceutical-segment level.

Base case

Pharmaceutical aluminum sulfate demand grows slowly with topical, oral, and specialty-product volumes. Suppliers maintain margins through quality premiums and long customer qualification cycles. Commodity cost inflation is passed through selectively.

Downside case

Demand declines if formulators replace aluminum sulfate with aluminum hydroxide, aluminum chloride, synthetic astringents, or other salts. Margin pressure increases if customers qualify multiple sources or if technical-grade suppliers move into higher-purity markets.

Upside case

Revenue improves if a new approved product adopts aluminum sulfate, if a supplier secures a multinational contract, or if customers seek a second source after supply disruptions. These events can materially increase the sales of an individual supplier while having little effect on the overall aluminum sulfate market.

Because public disclosures do not separate pharmaceutical-grade aluminum sulfate from broader chemical sales, company-level revenue exposure cannot be calculated reliably from filings alone. The best indicators are pharmaceutical customer additions, new GMP capacity, qualification activity, pricing commentary, and the share of specialty chemical revenue.

What is the generic launch risk for products containing aluminum sulfate?

Generic launch risk depends on the finished drug, not the excipient. The main scenarios are:

1. A generic manufacturer uses the same or equivalent aluminum sulfate grade and competes on price.
2. A supplier change triggers comparability, stability, or regulatory work.
3. A formulation patent expires while the excipient remains commercially available from multiple sources.
4. A product shifts to a substitute aluminum salt.
5. A contract manufacturer consolidates procurement across several products.

The excipient itself rarely prevents generic entry. Its importance is indirect: a tightly controlled grade can raise development and qualification costs, but it generally does not create durable exclusivity.

What is the biosimilar risk for aluminum sulfate?

Biosimilar competition is not directly relevant to aluminum sulfate. Biosimilars concern biological products and rely on a different regulatory framework from small-molecule excipients and conventional generic drugs.[8]

Aluminum sulfate can appear in a biologic or vaccine manufacturing process, but its presence does not make the excipient a biosimilar product. The relevant commercial risk is substitution between adjuvants or changes in manufacturing processes for the biologic.

What licensing deals or litigation affect aluminum sulfate?

No major publicly disclosed licensing structure is associated with aluminum sulfate as a standalone pharmaceutical excipient. Commercial arrangements are more likely to involve supply agreements, distribution contracts, quality agreements, and customer-specific qualification.

There is no broad, well-known Orange Book litigation trend centered on aluminum sulfate. Any litigation risk is likely to involve a finished topical or oral product, a manufacturing process, product liability, supply interruption, or a contractual dispute rather than ownership of the basic excipient.

What geographic markets offer the strongest opportunity?

Demand is strongest where pharmaceutical manufacturing, topical-product production, and specialty chemical distribution are concentrated.

Region	Commercial characteristics
North America	Strong regulatory documentation and established generic manufacturing
Europe	High quality and sustainability requirements; fragmented excipient sourcing
China	Large chemical production base and growing pharmaceutical manufacturing
India	Strong generic-drug and contract-manufacturing ecosystem
Latin America	Import dependence in some markets; distributor-led supply
Middle East and Africa	Water-treatment demand is larger than pharmaceutical demand

Geographic competitiveness depends on delivered cost, import rules, GMP documentation, local inventory, and the ability to support audits and regulatory submissions. A lower-cost producer may still lose business if it cannot provide stable specifications or timely change notifications.

Key Takeaways

• Aluminum sulfate is a niche pharmaceutical excipient within a much larger industrial and water-treatment market.
• Public companies do not separately disclose pharmaceutical aluminum sulfate revenue, preventing a reliable standalone market-size calculation.
• Revenue is driven by qualification premiums, supply reliability, and specialty documentation rather than patent exclusivity.
• The most relevant competitors are aluminum hydroxide, aluminum phosphate, aluminum chloride, and non-aluminum astringents.
• Orange Book listings, Paragraph IV challenges, and biosimilar competition apply to finished products, not to aluminum sulfate as a commodity excipient.
• Manufacturing quality, trace-metal control, hydration-state consistency, and change control are the principal commercial barriers.
• The base-case financial trajectory is stable, with low-to-moderate volume growth and pricing tied to sulfuric acid, alumina, energy, freight, and water-treatment demand.
• The strongest upside would come from adoption in a new approved product or a multinational supply contract.

FAQs

Is aluminum sulfate an FDA-approved pharmaceutical ingredient?

Aluminum sulfate is not approved as an independent drug. Its acceptability depends on its use as an inactive ingredient in a specific finished product and the supporting regulatory record.

Does aluminum sulfate have an Orange Book patent?

The excipient itself does not have an Orange Book patent listing. A finished drug containing aluminum sulfate could have listed patents if those patents meet FDA listing requirements.

Can aluminum sulfate be replaced by aluminum hydroxide?

Not automatically. The salts differ in chemistry, solubility, pH behavior, impurity profile, and formulation performance. Replacement requires product-specific development and regulatory assessment.

Is pharmaceutical-grade aluminum sulfate more profitable than industrial-grade material?

It can achieve a higher unit price, but the market is much smaller. Profitability depends on qualification costs, batch volumes, documentation, customer concentration, and the supplier’s ability to control raw-material and logistics expenses.

Who are the main buyers of pharmaceutical aluminum sulfate?

Buyers include drug-product manufacturers, topical-product companies, vaccine and biologic manufacturers where relevant to process or formulation applications, contract development and manufacturing organizations, and pharmaceutical ingredient distributors.

References

1. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
2. U.S. Geological Survey. (2024). Mineral commodity summaries 2024. U.S. Department of the Interior. https://pubs.usgs.gov/periodicals/mcs2024/
3. Chemtrade Logistics Income Fund. (2024). Annual report 2023. https://www.chemtradelogistics.com
4. Kemira Oyj. (2024). Annual report 2023. https://www.kemira.com
5. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application (ANDA): Generics. https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda
6. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th edition. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
7. International Council for Harmonisation. (2014). ICH Q3D(R2): Guideline for elemental impurities. https://www.ich.org/page/quality-guidelines
8. U.S. Food and Drug Administration. (n.d.). Biosimilars. https://www.fda.gov/drugs/therapeutic-biologics-applications-bla/biosimilars